SUMMARY Nine out of 14 patients treated with intraventricular methotrexate (MTX) for meningeal carcinomatosis from breast carcinoma and surviving more than 4 months developed disseminated necrotising leukoencephalopathy (DNL). All four patients who had received both intraventricular MTX and whole brain radiotherapy developed DNL. Five of the six patients who experienced an acute febrile reaction with mild encephalopathic signs following intraventricular administration of MTX developed DNL after a mean time of 5 months and a low mean dose of 44mg MTX. DNL was also noted in two patients without a previous febrile reaction or whole brain radiotherapy, following prolonged intraventricular MTX therapy after a mean time of 19 5 months and a mean dose of 147 mg MTX. These findings confirm the hazards of (1) high cumulative doses of intrathecal MTX and (2) toxic effect is disseminated necrotising leukoencephalopathy (DNL). It develops between 3 to 15 months after MTX administration and is clinically characterised by an insiduous onset of personality changes, lethargy and dementia, usually followed by hemiplegia or quadriparesis and coma.9 15
SUMMARY Nine out of 14 patients treated with intraventricular methotrexate (MTX) for meningeal carcinomatosis from breast carcinoma and surviving more than 4 months developed disseminated necrotising leukoencephalopathy (DNL). All four patients who had received both intraventricular MTX and whole brain radiotherapy developed DNL. Five of the six patients who experienced an acute febrile reaction with mild encephalopathic signs following intraventricular administration of MTX developed DNL after a mean time of 5 months and a low mean dose of 44mg MTX. DNL was also noted in two patients without a previous febrile reaction or whole brain radiotherapy, following prolonged intraventricular MTX therapy after a mean time of 19 5 months and a mean dose of 147 mg MTX. These findings confirm the hazards of (1) high cumulative doses of intrathecal MTX and (2) combined intrathecal chemotherapy and whole brain radiotherapy. This study also suggests a possible relationship between an early and transient febrile reaction during intraventricular administration of MTX and the development of DNL.
Intrathecal (IT) methotrexate (MTX) is widely used to treat or prevent meningeal leukaemia and lymphoma.' 2 It is also successfully applied in patients with meningeal carcinomatosis, particularly from breast carcinoma.3 5 Treatment is usually combined with cranial or craniospinal radiotherapy and occasionally with systemic MTX.
The neurological complications of intrathecal MTX administration can be divided into acute and late effects. The acute effects develop within hours and consist of a transient aseptic meningitis or, rarely, a myelopathy or encephalomyelopathy.6-8 The reported frequency of MTX meningitis varies from uncommon to more than 50%.9-l The symptoms of headache, vomiting and fever usually last 1 or 2 days. There is nuchal rigidity, usually, associated with a modest CSF pleiocytosis and elevated CSF protein. 9 The cause of this reaction is unknown and a number of factors have been implicated. 6 Probably MTX meningitis is caused by the drug itself, as it is usually accompanied by elevated CSF MTX levels.13 Active meningeal infiltration by malignant cells may be a predisposing factor.13 14 The most important delayed toxic effect is disseminated necrotising leukoencephalopathy (DNL). It develops between 3 to 15 months after MTX administration and is clinically characterised by an insiduous onset of personality changes, lethargy and dementia, usually followed by hemiplegia or quadriparesis and coma.9 15 Histological examination reveals areas of demyelination, axonal degeneration, astrocytosis and coagulative necrosis, predominantly in the periventricular white matter with or without vascular changes. 16 17 This appears on CT as periventricular areas of decreased density. This complication almost exclusively occurs when IT MTX is combined with cranial irradiation or systemic MTX and seems to be dosedependant. 6917 The incidence has been reported to be as much as 45% after high dose radiotherapy (>35 Gy) in combination with a larger dose of IT 
MTX.18
Hitherto only two patients have been described with DNL following IT MTX without additional cranial radiation or systemic MTX.'920 The administered total dose of MTX in these patients was 217 mg/m2 and 195mg/M2 respectively. The approximate risk of DNL due to IT MTX without whole brain radiotherapy or systemic MTX is assumed to be less than 1%, provided that a total dose of at least 50mg of MTX has been administered. 2' The present report analyses the occurrence of DNL in patients treated with IT period of fever in the four patients in whom IT MTX administration was continued. In three patients IT MTX was changed into cytosine arabinoside (ARA-C), given in a dose of40 mg in 2 ml of preservative-free water. In Patient 4 a total dose of 160mg ARA-C was given because of simultaneous whole brain radiotherapy for parenchymal metastases. Patient 6 received 40 mg ARA-C because of the febrile reaction during IT MTX. As fever persisted ARA-C was also discontinued. In addition, no relation could be found between the in patients without acute development of DNL and the area or intensity of ,yer et al. 13 Neuropathological examination showed macroscopically visible foci of necrosis and demyelination in the cerebral periventricular white matter in both patients with DNL examined (fig 3) . In Patient 5 these foci were predominantly located in the direct vicinity of the ventricles.
For microscopical examination haematoxylin and eosin, Kluver, PAS and Kossa stains were used. In both patients tumour cells were found in most parts of the subarachnoid space. In Patient I a section of the right frontal area showed necrotic lesions, surrounding small areas with relatively intact white matter. In the necrotic lesions macrophages were seen and fields of astrocytosis. The vessels in these areas were thickened by fibrinoid necrosis, with hyalinisation and narrowing of the lumen without real occlusion. The Kossa stain was negative. Microscopical examination of both frontal areas in Patient 5 demonstrated necrotic areas in the white matter with myelin degeneration, cellular remnants, macrophages and some glial reaction and vascular proliferation ( fig  4) . Hyalinoid and fibrinoid-necrotic changes of blood vessel walls were seen with narrowing of the lumen occasionally with complete occlusion. Amyloid was not observed. The Kossa stain for calcium in the vessel walls was slightly positive.
Discussion
The acute febrile reaction following intrathecal administration of preservative-free MTX in six patients in the present study differs clearly from MTX meningitis. Fever gradually developed after the second or third dose of MTX without an obvious relation to the moment of injection while it lasted much longer than 1 or 2 days. There were in fact no signs of a meningeal reaction. Nuchal rigidity was absent and CSF did not show a cellular reaction or elevated protein. No significant relation was found with elevated CSF MTX levels, nor with the area or intensity of the malignant meningeal involvement. The dose of MTX per injection in our patients was lower than usually applied.346 11 DNL almost exclusively occurs when IT MTX is combined with whole brain radiotherapy and/or systemic MTX.9 17 The incidence of DNL increases with the cumulative dose of IT MTX'7 and may be correlated with elevated CSF MTX levels.22 The present study shows a clear relation between DNL and (1) whole brain radiotherapy (2) the cumulative dose of MTX and (3) an early febrile reaction. No close relation was found between the occurrence of DNL and ventricular CSF MTX levels. The patients with a febrile reaction developed DNL after a short interval and following a low dose of MTX. Two of these patients had also received whole brain radiotherapy. However, as in both patients IT MTX had been stopped before radiotherapy it is questionable whether radiotherapy has substantially contributed to the development of DNL.9 14 Moreover, the total dose of 1750 cGy in 12 fractions in one of these patients is lower than the estimated minimal neurotoxic dose. 6 17 Only two cases of DNL following IT MTX without radiotherapy or systemic MTX have been previously described.'920 The cumulative dose of IT an early transient decreased CSF flow.
For the development of DNL following MTX several mechanisms have been considered. 520 28 -30 Apart from the direct toxic effect of MTX on glial and endothelial cells, the mental changes have been related to deficiencies of folic acid, serotonin and biogenic amines, caused by MTX.2829 The neurotoxic effect of MTX is potentiated by cranial irradiation which induces endothelial damage resulting in an increased diffusion of MTX into the brain parenchyma. 1728 The predilection for the periventricular white matter has been explained by impaired CSF flow from the ventricles with increased transependymal diffusion.16 Impaired flow over the convexities with increased absorption from the deep Virchow-Robin spaces may be a contributing factor.20 The absence of DNL after prophylactic treatment with IT MTX31 is in agreement with the significance of CSF flow disturbances due to the neoplastic meningitis. Postmortem examination in Patient 5 showing predominance of demyelination and necrosis in the direct vicinity of the lateral ventricles suggests that a pathologic transependymal diffusion of MTX may also occur at so called non-toxic ventricular CSF MTX levels.
A sensitisation or hypersensitivity response, as proposed in some other cases of MTX neurotoxicity32 -34 can not be excluded as an underlying mechanism in causing the acute febrile reaction and DNL after low dose of MTX. However, disappearance of the fever during continued MTX administration is not in accordance with this hypothesis. ARA-C may cause DNL after high dose iv infusion35 but not after intrathecal administration36 and therefore did not contribute to the development of DNL in our patients. The neuropathological findings show that apparent irradiation specific vascular changes can also be produced by IT MTX alone. Histologically, there was no striking difference between the two examined patients, although in Patient 1 the lesions can be interpreted as more acute. This patient had experienced a rapidly progressive course of the disease and only lived 1 month after the first signs of DNL. It may be speculated whether previous whole brain radiotherapy in this patient has played a role in the rapid development of these extensive necrotic lesions.
This study shows that DNL is not a rare complication of IT MTX therapy. The incidence is related to the cumulative dose of MTX and the duration of treatment as well as to whole brain radiotherapy. In addition, DNL may be induced by less than 50 mg IT MTX in patients who have developed an acute reaction to IT MTX that consists of fever and mild
